表紙
市場調査レポート

出生前診断の世界市場

Prenatal Diagnostics

発行 Global Industry Analysts, Inc. 商品コード 248920
出版日 ページ情報 英文 197 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.85円で換算しております。

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

Back to Top
出生前診断の世界市場 Prenatal Diagnostics
出版日: 2016年06月01日 ページ情報: 英文 197 Pages
概要

当レポートでは、出生前診断の世界市場を取り上げ、米国、カナダ、日本、欧州、アジア太平洋、ラテンアメリカ、およびその他の地域など、地域ごとの個別分析を行うとともに、各地域について過去の実績および将来の予測を提供し、主要企業およびニッチ企業38社のプロフィールをまとめるなど、概略以下の構成でお届けします。

第1章 イントロダクション、調査方法、製品定義

  • 調査の信頼性とレポートの制約
  • 免責事項
  • データの解釈とレポートのレベル
    • 定量技法および分析法
  • 製品の定義と調査範囲

第2章 エグゼクティブサマリー

  • 全体的な概要
    • 拡大が見込まれる出生前検査市場
    • 出生前検査:妊娠治療分野を変える
    • 出生前検査:基本的概要
    • 提供されている出生前スクリーニングおよび診断検査の適応別リスト
    • 染色体異常が出生前検査分野における主導的症状
    • 遺伝子検査が遺伝的症状の診断に大きな役割を果たす
    • 出生前遺伝子検査の原理
    • 出生前遺伝子検査の台頭
    • 非侵襲性出生前検査:ずっと先のこと
  • 産業概要
    • 出生前治療の必要性:出生前検査の基礎
    • 早産を取り扱う際の出生前検査の役割
    • カウンセリング:出生前検査前後の不可欠な手続
    • 出生前検査市場の促進に向けて実現勢力が出揃う
    • 感度と特異性が低い既存検査:新たな検査のケースが準備中
    • 感度の高い血清検査は導入者が少ない可能性がある
    • 従来型出生前診断手法:リスクのある方法
    • 既存侵襲性技法におけるその他の否定的要素
    • NIPD(非侵襲性出生前診断)は従来型診断手順におけるリスクと不確実性を排除
    • NIPD技法に対する反対意見:導入に向けた大きな障害
    • 倫理問題が出生前検査の恩恵と普及を行き詰らせる
    • NIPD検査の恩恵は障害を上回る
    • NIPD検査の普及に影響を及ぼす主要な要素
    • スクリーニング検査との置き換え:NIPDによる想像可能な変化
    • ありそうな多様なNIPDの利用
    • 超音波:血液ベースのスクリーニング検査との必須の組み合わせ
  • アプリケーション概要
    • 染色体異常:大きな経済的負担
    • 遺伝障害の事象別、遺伝的発現別、および患者数リスト
    • 出生前ダウン症検査における大きな機会が存在
    • T21のスクリーニングおよび確認のための主要なスクリーニング検査のリスト
    • 非侵襲性出生前診断にはより大きな有用性の可能性が存在
    • ダウン症スクリーニング/診断技法
    • SequenomのT21検査にとっての機会
    • ダウン症を超えて:追加の対象を検査することが極めて重要
    • Trisomy 18(トリソミー18)もしくはエドワーズ症候群:概要
    • Trisomy 13(トリソミー13)もしくはパト―症候群:概要
    • 嚢胞性線維症のスクリーニングおよび診断
    • 嚢胞性線維症スクリーニング市場:極めて断片的
  • 技術概要
    • DNA:全細胞よりもNIPD分析に最も適したターゲット
    • 出生前検査における満たされていない要求:新技術および検査を促進する重要な要素
    • 出生前検査におけるシーケンシング:潜在的な高成長市場
    • NIPI検査における現在の分析手法の概要
    • 非侵襲性出生前診断に用いられる競合技術の比較
    • 侵襲性手順由来サンプルの分析に使われる主要な技術
    • 染色体分析
    • 蛍光in situハイブリダイゼーション(FISH法)
    • デジタルPCR:胎児異数性検知の領域に踏み込む
    • 大規模並列ショットガン配列決定:検査結果までの時間の短縮化を可能に
    • 出生前診断の分野を援助するBioCepの新技術
    • 出生前診断における増加が見込まれるマイクロアレイベース検査
    • NIPDにおける全ゲノムシーケンシング技術:新たな進展
    • 胎児DNAが出生前診断の領域に変革をもたらす
    • SequenomがCCFF核酸検査に対する権利の取得により大きく飛躍
    • 超音波ベーススクリーニングに新たな副ターゲットを準備中
  • 競合環境
  • 製品概要
    • 出生前検査
    • 出生前診断検査を推奨する際の検討要素
    • 出生前検査の種類
    • 出生前スクリーニング検査
    • 出生前診断検査
  • 製品の革新/発表
  • 業界における最近の動き
  • 主要な国際企業
    • Angle Plc(英国)
    • Hologic, Inc.(米国)
    • PerkinElmer, Inc.(米国)
    • Ravgen, Inc.(米国)
    • Sequenom, Inc.(米国)
    • Sequenom Center for Molecular Medicine, LLC(米国)
    • TrovaGene, Inc.(米国)
  • 世界市場の展望

第3章 市場

  • 米国
  • カナダ
  • 日本
  • 欧州
    • フランス
    • ドイツ
    • イタリア
    • 英国
    • その他欧州
  • アジア太平洋
  • その他の地域

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: MCP-7675

This report analyzes the worldwide markets for Prenatal Diagnostics in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 43 companies including many key and niche players such as -

ANGLE Plc
Ariosa Diagnostics, Inc.
BGI Diagnosis Co., Ltd.
Berry Genomics Co., Ltd.
Hologic, Inc.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study
    • Prenatal Testing
      • Prenatal Screening Tests
      • Prenatal Diagnostic Tests
        • Non-Invasive Prenatal Diagnostic Tests

II. EXECUTIVE SUMMARY

1. GLOBAL OUTLOOK

  • Prenatal Testing Market to Rise
  • Prenatal Testing - Changing the World of Pregnancy Care
  • Prenatal Testing - An Rudimentary Overview
  • List of Available Prenatal Screening and Diagnostic Tests by Indication
  • Chromosomal Abnormalities Lead the Prenatal Testing Space
  • Genetic Testing Plays Pivotal Role in Diagnosing Inherited Conditions
  • The Rationale for Prenatal Genetic Testing
  • The Rise of Prenatal Genetic Testing
  • Non-Invasive Prenatal Diagnostics - The Way Ahead

2. INDUSTRY OVERVIEW

  • Need for Prenatal Care - A Base for Prenatal Testing
  • Role of Prenatal Testing in Managing Preterm Births
  • Counseling - An Imperative Measure Before and After Prenatal Testing
  • Enabling Forces Line Up to Drive Prenatal Testing Market
  • Lower Sensitivity and Specificity of Existing Tests - A Case for New Tests on the Anvil
    • Table 1: List of Available Prenatal Screening/ Diagnostic Tests by Accuracy
  • High Sensitivity Serum Tests May Not Have Many Takers
  • Conventional Pre-Natal Diagnostic Techniques - A Risky Affair
  • Other Negativities of Existing Invasive Techniques
  • NIPD Eliminates Risks and Uncertainty of Conventional Diagnostic Procedures
  • Opposition to NIPD Technique - A Significant Hurdle to Adoption
  • Ethical Issues Bog Down Benefits and Proliferation of Prenatal Testing
  • Benefits Outweigh Snags in NIPD Tests
  • Major Factors Influencing Penetration of NIPD Tests
    • Table 2: Price Comparison of Existing Tests and Screening Procedures for Down's Syndrome
  • Replacing Screening Tests - A More Conceivable Change through NIPD
  • Diversity in NIPD Usage on the Cards
  • Ultrasound - An Indispensable Combination with Blood Based Screening Tests

3. APPLICATION OVERVIEW

  • Chromosomal Abnormalities - A Substantial Economic Burden
  • List of Genetic Disorders by Event, Genetic Manifestation and Prevalence
  • Significant Opportunity Exists for Prenatal Down's Syndrome Testing
  • List of Select Screening Tests Available for T21 Screening and Confirmation
  • Broader Utility Potential Exists for Non-Invasive Prenatal Diagnosis
  • Down's Syndrome Screening/Diagnostic Techniques
  • Opportunities for Sequenom's T21 Test
  • Beyond Down's Syndrome - Need to Test Additional Targets Crucial
  • Trisomy 18 or Edward's Syndrome - An Overview
  • Trisomy 13 or Patau Syndrome - An Overview
    • Rationale for Screening Tests in T13 and T18
  • Cystic Fibrosis Screening and Diagnosis
  • Cystic Fibrosis Screening Market - Highly Fragmented

4. TECHNOLOGY OVERVIEW

  • DNA - The most Ideal Target for NIPD Analysis than Whole Cells
  • Unmet Need in Prenatal Testing - A Key Driver for New Technologies and Tests
  • Sequencing in Prenatal Testing - A Potential High Growth Market
  • Overview of Current Analysis Methods for NIPD Tests
  • Comparison of Competitive Technologies Employed in Invasive Prenatal Diagnosis
  • Major Technologies Used in Analyzing Invasive Procedure-Derived Samples
  • Karyotyping
  • Fluorescence in situ hybridization (FISH)
  • Digital PCR - Entering the Realm of Fetal Aneuploidy Detection
    • Lower DNA Percentage Stifles Rapid Progression in Digital PCR Utility Research
  • Massively Parallel Shotgun Sequencing - Enabling Shorter Time to Test Results
  • BioCep Novel Technology to Aid Prenatal Diagnostic Space
  • Microarray-Based Testing to See a Boost in Prenatal Diagnosis
  • Whole Genome Sequencing Technology in NIPD - A New Advancement
  • Free Fetal DNA Revolutionizes Prenatal Diagnosis Arena
  • Sequenom Takes a Giant Leap with Acquisition of Rights to CCFF Nucleic Acid Testing
  • New Sub-Targets on the Anvil for Ultrasound- Based Screening

5. COMPETITIVE ENVIRONMENT

  • Competition Intensifies in the NIPD Market
  • Select Companies Marketing/Developing NIPD (Genetic) Tests
  • Sequenom - A Major Player in the Non-Invasive Pre-natal Test Space
  • Sequenom's Product Pipeline for Prenatal Diagnostics -Launched and Under-Development Tests
  • Undulating Journey of Sequenom in the NIPD Space
    • SEQureDx - A Breakthrough Testing Platform from Sequenom in Vain
    • SEQureDx - An Alternative for Amniocentesis in RhD Status Determination
  • Sequenom's LDT Approach to Market for T21 Test - An Overview
    • Sequenom's Alliances in the Area of Genetic Testing
  • The Changing Regulatory Paradigm of LDT
  • Companies Already at Patent War in NIPD Space
  • Verifi(tm) Joins the League of NIPD Tests but Becomes the First Commercial Test
  • Verinata's Approach to the Market for the Verifi(tm) Test - An Insight
  • TrovaGene's Transrenal Technology - A New Breakthrough in NIPD
  • Aria Diagnostics Kick Starts the First of its Kind Trial for Non-Invasive Prenatal Test
  • Perkin Elmer Strengthens Testing Domain Post CVS or Amniocentesis
  • Overview of Select Launched/Under Development NIPD Tests
  • MaterniT21(tm) (Sequenom)
  • SensiGene Fetal (XY) - Sequenom
  • SensiGene Cystic Fibrosis Carrier Screening Test - Sequenom
  • SensiGene Fetal RhD - Sequenom
  • RareCellect(tm) (Genetic Technologies)

6. PRODUCT OVERVIEW

  • Prenatal Testing
  • Factors Considered for Recommending Prenatal Diagnostic Testing
  • Types of Prenatal Testing
  • Prenatal Screening Tests
    • Evolution of Screening Tests
    • Ultrasound
      • Types of Ultrasound
      • Ultrasound Examination Types and Use in Prenatal Screening of Fetus
    • Triple Screen Test
    • Quad Screen Test
  • Prenatal Diagnostic Tests
    • Chorionic Villus Sampling
      • The Procedure
      • Risks
    • Amniocentesis
      • The Procedure
      • Risks
    • Cordocentesis
      • Procedure
      • Risks
    • Non-Invasive Prenatal Diagnostic Tests

7. PRODUCT INNOVATIONS/LAUNCHES

  • Verinata Rolls Out Verifi(tm) NIPD Test for Common Chromosomal Abnormalities
  • Sequenom CMM Expands Test Offering of MaterniT21(tm)
  • DNA Diagnostics Centre Introduces Non-Invasive Prenatal Paternity Test
  • GSN Introduces Bioinformatics Technology-based Noninvasive Prenatal Test
  • Sequenom CMM Introduces Non-invasive MaterniT21(tm) LDT
  • PerkinElmer Signature Genomic Laboratories Launches Signature Precision Panel(tm) | Prenatal Diagnostic Test
  • Sequenom Center for Molecular Medicine Introduces SensiGene(tm) Fetal(XY) Test
  • Helicos BioSciences to Launch Molecular Diagnostic Tests
  • QIAGEN Unveils QIAamp Circulating Nucleic Acid Kit

8. RECENT INDUSTRY ACTIVITY

  • Aria Diagnostics Commences Clinical Trial Prenatal Trisomy 21 Test
  • Aria Diagnostics Secures New Funding
  • Sequenom Signs Licensing Agreement with Isis Innovation
  • Verinata Health Enters into Supply Agreement with Illumina
  • DDC Unveils Noninvasive Prenatal Paternity Test
  • TrovaGene Reacquires Transrenal MDx Technology Rights from Sequenom
  • Sequenom, LifeCodexx Ink European Licensing Agreement
  • Sequenom Ink Multi-Year Supply Deal with Illumina
  • LifeCodexx and GATC Biotech Initiate Clinical Validation Study for NIPD Test
  • Sequenom and New England Biolabs Enter into Licensing and Co-marketing Agreement
  • KellBenx, Cedars-Sinai Medical Center Ink Global Licensing Agreement for Biomarker Technology
  • KellBenx Secures Global License for Commercializing AdnaGen Antibodies
  • Cytyc and Hologic Merge
  • PerkinElmer Takes Over Surendra Genetic Labs
  • Sequenom Center for Molecular Medicine Inks Agreement with PDI

9. FOCUS ON SELECT GLOBAL PLAYERS

  • Angle Plc (UK)
  • Hologic, Inc. (The US)
  • PerkinElmer, Inc. (The US)
  • Ravgen, Inc. (The US)
  • Sequenom, Inc. (The US)
  • Sequenom Center for Molecular Medicine, LLC (The US)
  • TrovaGene, Inc. (The US)

10. GLOBAL MARKET PERSPECTIVE

    • Table 3: World Recent Past, Current & Future Analysis for Prenatal Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart)
    • Table 4: World 10-Year Perspective for Prenatal Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2009, 2012 & 2018 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Current & Future Analysis
    • Popularity of Screening and ACOG Guidelines Sink Invasive Prenatal Diagnosis Numbers
    • Table 5: US Annual Pregnancies by Age Group/ Risk Profile: 2010 (includes corresponding Graph/Chart)
    • Tough Market Prospects for Sex Determination Tests
    • Sequenom Bets Big on MaterniT21
    • Product Launches
    • Strategic Corporate Developments
    • Select Players
  • B. Market Analytics
    • Table 6: US Recent Past, Current & Future Analysis for Prenatal Diagnostics - Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart)

2. CANADA

  • Market Analysis
    • Table 7: Canadian Recent Past, Current & Future Analysis for Prenatal Diagnostics- Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart)

3. JAPAN

  • Market Analysis
    • Table 8: Japanese Recent Past, Current & Future Analysis for Prenatal Diagnostics- Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • Current & Future Analysis
    • Strategic Corporate Developments
  • B. Market Analytics
    • Table 9: European Recent Past, Current & Future Analysis for Prenatal Diagnostics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart)
    • Table 10: European 10-Year Perspective for Prenatal Diagnostics by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2009, 2012 & 2018 (includes corresponding Graph/Chart)

4a. FRANCE

  • Market Analysis
    • Table 11: French Recent Past, Current & Future Analysis for Prenatal Diagnostics - Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart)

4b. GERMANY

  • Market Analysis
    • Table 12: German Recent Past, Current & Future Analysis for Prenatal Diagnostics - Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart)

4c. ITALY

  • Market Analysis
    • Table 13: Italian Recent Past, Current & Future Analysis for Prenatal Diagnostics - Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM

  • A. Market Analysis
    • Current & Future Analysis
    • Increasing Need for Less Risky Prenatal Diagnostic Methods in the UK
    • Product Launch
    • Strategic Corporate Development
    • Angle Plc - A Key Regional Player
  • B. Market Analytics
    • Table 14: UK Recent Past, Current & Future Analysis for Prenatal Diagnostics - Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart)

4e. REST OF EUROPE

  • A. Market Analysis
    • Current & Future Analysis
    • Product Launch
  • B. Market Analytics
    • Table 15: Rest of Europe Recent Past, Current & Future Analysis for Prenatal Diagnostics - Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • Market Analysis
    • Table 16: Asia-Pacific Recent Past, Current & Future Analysis for Prenatal Diagnostics - Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart)

6. REST OF WORLD

  • Market Analysis
    • Table 17: Rest of World Recent Past, Current & Future Analysis for Prenatal Diagnostics- Analyzed with Annual Revenue Figures in US$ Million for Years 2009 through 2018 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Back to Top